Scilex Holding Co (SCLXW) cash flow statement

SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30

$0.04−0.00 (-1.53%)

Close on Oct 30, 2026Market cap $17.50MP/E –Yield –

Scilex Holding Co cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	4.62	4.05	4.15	3.96	3.78	3.78
Stock-Based Compensation	15	16	15	5.28	5.82	5.40
Deferred Income Taxes	14	-19	-28	-12	-15	-4.10
Change in Accounts Receivable	14	-6.27	-13	-6.97	-1.14	-0.60
Change in Inventory	1.80	1.46	-2.84	1.18	-1.42	2.38
Change in Accounts Payable	15	-8.17	2.31	-0.12	0.66	-1.07
Operating Cash Flow	3.82	19	-21	-21	-29	-31
Capital Expenditures	-0.13	0	-0.03	-0.01	0	-0.03
Investing Cash Flow	4.08	-2.68	-0.33	-2.07	0	-0.03
Dividends Paid	–	-8.65	-8.65	–	–	–
Stock Issued	–	–	35	0	0	–
Debt Issued	0	25	0	–	–	–
Debt Repaid	0	-64	-5.00	–	–	–
Financing Cash Flow	-5.46	-18	24	21	28	-19
Foreign Exchange Rate Adjustments	-0.76	0	–	–	–	–
Net Change in Cash	1.68	-1.46	2.55	-2.15	-0.50	-51
Free Cash Flow	3.68	19	-21	-21	-29	-31
Income Taxes Paid	0.02	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 161.1%
Operating margin: -1136.4%
Net margin: -1469.8%
Return on equity, FY2025: 186.8%

Financial strength

Current ratio: 0.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.1%

Valuation

P/E ratio: –
Price to sales: 0.55
Price to book: –
Dividend yield: –